Lexaria Bioscience Corp. develops and licenses DehydraTECH, a patented oral drug delivery formulation and processing platform designed to improve how active pharmaceutical ingredients enter the bloodstream. News about LEXX centers on GLP-1 drug delivery research, DehydraTECH-semaglutide compositions, preclinical and human study updates, intellectual property activity, and pharmaceutical partner evaluations under material transfer arrangements.
Company updates also cover Lexaria's investor communications, oral drug delivery market commentary, and applications of DehydraTECH across pharmaceuticals, nutraceuticals, over-the-counter products, and consumer formats. Recurring themes include bioabsorption, tolerability, blood-brain-barrier delivery, research laboratory activity, and the company's IP licensing business model.
Lexaria Bioscience Corp. held its 2021 Annual Meeting on June 28, with 2,735,413 shares represented, comprising 53.6% of its issued capital. Shareholders voted on several proposals, including the election of directors and the appointment of auditors. Key votes included 97.2% approval for Chris Bunka's directorship and 99.2% for auditor appointment. However, an amendment to the Equity Incentive Plan was only 68.3% approved. The company’s DehydraTECH technology continues to enhance drug delivery capabilities across various products, with a robust patent portfolio.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reports promising results from its study VIRAL-A20-2, demonstrating that its DehydraTECH technology significantly enhances the oral bioavailability of remdesivir and ebastine. Findings indicate that drug levels in the bloodstream can be increased by up to three times compared to non-processed drugs. This improvement may increase the efficacy of these antiviral drugs against SARS-CoV-2. The study was conducted on male rats, with results showing significant improvements in drug delivery metrics.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has provided a progress report on its 2021 applied R&D program, focusing on the enhanced drug delivery capabilities of its DehydraTECH technology. Significant studies include tolerability and pharmacokinetic evaluations for antiviral drugs and blood pressure testing using CBD. Key studies reported include VIRAL-A20-2 and VIRAL-A20-3 for antiviral drugs, and follow-up studies on blood pressure and NSAIDs. All studies are fully funded and aim to establish commercial partnerships.
Lexaria Bioscience Corp. has completed dosing in its first human clinical study, HYPER-H21-1, testing the efficacy of its DehydraTECH 2.0 CBD formulation for hypertension treatment. The study involved 24 participants aged 45 to 65, all of whom tolerated the treatment well with no serious adverse effects. Preliminary results are expected by July or August 2021, ahead of the previous Q3 timeline. The company is set to commence the second study, HYPER-H21-2, shortly, involving 16 participants and aiming for swift data analysis and reporting.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced that its DehydraTECH technology effectively inhibited the COVID-19 SARS-CoV-2 virus in an in vitro study using remdesivir and ebastine. The study's preliminary results confirmed the antiviral efficacy of these compounds, paving the way for future in vivo testing. The global antiviral market is projected to exceed USD $44 billion by 2026. Lexaria aims to enhance the oral delivery of these drugs, addressing key challenges in their bioavailability.
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) announced remarkable results from its latest DehydraTECH 2.0 cannabidiol (CBD) formulation, achieving a 2,708% improvement in CBD absorption compared to the standard MCT control. This formulation outperformed previous versions, increasing efficacy by 174% over the original DehydraTECH 2.0. The ongoing HYPER-H21-1 human clinical hypertension study is expected to further validate these advancements. Lexaria's research, focused on enhancing drug delivery, positions it favorably in the burgeoning CBD market.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has announced its first patent grant in India, expanding its intellectual property portfolio to a total of 19 patents worldwide. This new patent, titled Stable ready-to-drink beverage compositions comprising lipophilic active agents, is valid for 20 years from December 1, 2016. The patent enhances Lexaria's existing protections in the EU, U.S., and Australia, allowing innovation in ready-to-drink beverages that include various active ingredients like NSAIDs and cannabinoids. Lexaria's patented technology, DehydraTECH™, improves the bio-absorption of these compounds.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced favorable results from its first animal study and the initiation of its first human clinical study as part of its 2021 Hypertension R&D program. CEO Chris Bunka will present at the Benzinga Global Small Cap Conference on May 13, 2021, at 3:50 p.m. ET. The presentation will cover Lexaria's DehydraTECH™ drug delivery technology and its effectiveness in enhancing the delivery of cannabidiol (CBD) for hypertension and other applications. The event aims to connect small-cap companies with investors.
Lexaria Bioscience Corp. (NASDAQ:LEXX, NASDAQ:LEXXW) announced successful results from its 2021 study HYPER-A21-1, showcasing its DehydraTECH 2.0 formulations. These new formulations delivered up to 2,178% more CBD into the bloodstream and 1,737% more into brain tissue compared to a standard MCT oil control. The study involved ten rats receiving a 25 mg/Kg dose of CBD over 120 minutes. CEO Chris Bunka emphasized the substantial absorption efficiency of these formulations, which are anticipated to have applications in both pharmaceutical and consumer product markets.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has launched its human clinical hypertension study HYPER-H21-1, examining the effectiveness of its patented DehydraTECH CBD formulation in controlling blood pressure. The study involves 24 volunteers and aims to complete dosing within weeks, with preliminary results expected by July. Secondary objectives include assessing the absorption rate of CBD and related metabolites. Lexaria has 18 granted patents and anticipates further studies to support DehydraTECH's validity as a hypertension treatment. Final results are scheduled for early September 2021.